The use of serum tumor markers in the management of patients with malignancy.
Markman
M
M
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D003110:Colonic Neoplasms / Q000097:blood / Q000276:immunology; D005260:Female; D006801:Humans; D015166:Monitoring, Immunologic / Q000379:methods*; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D009369:Neoplasms / Q000628:therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000097:blood / Q000276:immunology; D010051:Ovarian Neoplasms / Q000097:blood / Q000276:immunology; D010446:Peptide Fragments / Q000097:blood; D016879:Salvage Therapy; D016896:Treatment Outcome; D000509:alpha-Fetoproteins / Q000032:analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D010446:Peptide Fragments; D000509:alpha-Fetoproteins